Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 21;11:1003. doi: 10.1038/s41467-020-14740-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Timeline showing injection of Cre-dependent inhibitory DREADD (iDREADD) virus to dmPFC of adult PV-Cre mice and subsequent repeated measures behavioral design. For CNO (red square) and SAL (gray square) injections, each mouse is tested under both CNO and SAL conditions, and the order is counterbalanced for each behavior test. b Representative injection of inhibitory DREADD injected in dmPFC of PV-Cre mouse (left, scale bar = 100 μm) and co-localization of DREADD virus expression (mCherry, red) with PV staining (blue) (right, scale bar = 50 μm). c Validation of iDREADD in dmPFC-PVI. Left: representative trace of whole-cell recording from a PVI in adult dmPFC slice upon CNO bath application. Right: change in membrane potential from vehicle after CNO application. Repeated measures t test, t = 16.68, df = 5, ***p < 0.001, n = 6 cells from three mice. d Three-chamber tests show trending decreases in time in social chamber (top), and significant decreases in time interacting per social chamber entry (bottom) when PVIs are suppressed with CNO, compared with saline. (n = 9 mice. Two-way repeated measures ANOVA, effect of the drug: F(1,8) = 4.39, p = 0.07 (top), F(1,8) = 14.28, p = 0.005 (bottom)). e No effect of the drug was seen on distance traveled (top) or time in the center vs. periphery (bottom) in an open-field test (two-way repeated measures ANOVA, distance traveled: effect of the drug, F(1,7) = 0.01, p = 0.92, time in the center: effect of the drug, F(1,7) = 0.21, p = 0.66, n = 8 mice), or in f the light–dark (LD) box test in either time in the dark (top) or time in the light (bottom), (paired t test, time in light: t = 1.089, df = 8, p = 0.31, time in the dark: t = 1.16, df = 8, p = 0.28, n = 9 mice). All error bars reflect + /− SEM. See related Supplementary Figs. 5 and 6. Source data are available as a Source Data file.